Potentiation of the Hypotensive Effect of Bradykinin by Short-term Infusion of Angiotensin-(1-7) in Normotensive and Hypertensive Rats

Hypertension

Volumn 30, Issue 3, 1997, Pages 542-548

  Lima, Celso V ^a   Paula, Renata D ^a   Resende, Fernanda L ^a   Khosla, Mahesh C ^a   Santos, Robson A S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BRADYKININ; DRUG SYNERGISM; HYPERTENSION; MALE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, WISTAR;

EID: 0030765388     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.30.3.542     Document Type: Article

References (35)

1. Nephrology Forum (Principal discussant: Irene Gavras). Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992;42:1020-1029.
2. Hecker M, Porsti I, Busse R. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors. Braz J Med Biol Res. 1994;27:1917-1921.
3. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol. 1993;22(suppl 5):S31-S36.
4. Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
5. Santos RAS, Campagnole-Santos MJ. Central and peripheral actions of angiotensin-(1-7). Braz J Med Biol Res. 1994;27:1033-1047.
6. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439-449.
7. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides. 1993;14:883-891.
8. Santos RAS, Brosnihan KB, Chappell MC, Pesquero JL, Chernicky CL, Greene LJ, Ferrario CM. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. 1988;11:153-157.
9. Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 1992;19(suppl II):II-56-II-61.
10. Kono T, Taniguchi A, Imura H, Oseko F, Khosla MC. Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man. Life Sci. 1986;38:1515-1519.
11. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin (1-7). Peptides. 1993;14:679-684.
12. Meng W, Busija DW. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke. 1993;24:2041-2045.
13. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993;234:35-42.
14. Brosniham KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
15. Paula RD, Lima CV, Khosla MC, Santos RAS. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995;26(pt 2):1154-1159.
16. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira DR, Caligiorne SM, Rodrigues ARV, Gropen C Jr, Carvalho WS, Simoes e Silva AC, Khosla MC. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull. 1994;35:293-298.
17. Abduhl P, Felix D, Khosla MC. [7-D-Ala]-Angiotensin-(1-7): selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res Bull. 1994;35:289-291.
18. Fontes MAP, Silva LCS, Campagnole-Santos MJ, Khosla MC, Guertzenstein PG, Santos RAS. Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventrolateral medulla acting through specific receptors. Brain Res. 1994;665:175-180.
19. Fontes MAP, Pinge MC, Naves V, Campagnole-Santos MJ, Lopes OU, Khosla MC, Santos RAS. Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats. Brain Res. 1997;750(1-2):305-310.
20. Li P, Chappell MC, Ferrario CM, Brosniham KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29(pt 2):394-400.
21. Salgado MCO, Krieger EM. Acute changes in the renin-angiotensin system modify bradykinin and angiotensin reactivity and metabolism in conscious rats. Hypertension. 1983;5(suppl V):V-172-V-176.
22. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994;111:652-654.
23. Oliveira DR, Santos RAS, Santos GFP, Khosla MC, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension. 1996;27:1284-1290.
24. Diz DI, Ferrario CM. Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin-(1-7). In: Raizada MK, Phillips MI, Sumners C, eds. Recent Advances in Cellular and Molecular Aspects of Angiotensin Receptors. New York, NY: Plenum Press; 1996:225-235.
25. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 1997;29(pt 2):338-393.
26. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992;19:138-145.
27. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
28. 2 activity and sodium transport by angiotensin-(1-7). Kidney Int. 1993;44:932-936.
29. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension. 1990;15:475-481.
30. Kauser K, Rubanyi GM. Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension. 1995;25(pt 1):517-523.
31. Matsufuji H, Matsui T, Ohshige S, Kawasaki T, Osajima K, Osajima Y. Antihypertensive effects of angiotensin fragments in SHR. Biosci Biotech Biochem. 1995;59:1398-1401.
32. Salgado MCO, Krieger EM. Hyperreactivity to bradykinin and alterations in angiotensin I conversion and bradykinin inactivation in renal hypertensive rats. Hypertension. 1982;4:77-83.
33. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
34. Jaiswal N, Tallant EA, Jaiswel RK, Diz DI, Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther. 1993;265:664-673.
35. Nolly H, Carretero OA, Scicli AG. Kallikrein release by vascular tissue. Am J Physiol. 1993;265:H1209-H1214.